Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease

  • Castro M
  • Whitcomb B
  • Zajchowski D
  • et al.
N/ACitations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

PURPOSE Compared to other subtypes of epithelial ovarian cancer, clear cell carcinoma of the ovary bears an ominous reputation for chemotherapy resistance, increased relapse rate, and diminished survival. Among patients with distinct histopathologic subtypes, molecular analyses have identified a variety of known drivers of the malignant behavior, and depict a striking heterogeneity. METHODS A patient with rapidly metastatic CCCO that was refractory to taxane, platinum, pemetrexed, and bevacizumab-based strategies underwent molecular profiling which disclosed dual MAPK and PI3K/AKT/mTOR pathway mutations. RESULTS Combined targeted therapy with trametinib and metformin resulted in a dramatic disease regression without toxicity. CONCLUSION The case highlights the utility of precision medicine combining individual molecular diagnosis with rational therapeutic intervention with targeted agents.

Cite

CITATION STYLE

APA

Castro, M. P., Whitcomb, B. P., Zajchowski, D. A., & Coleman, R. L. (2015). Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease. Gynecologic Oncology Research and Practice, 2(1). https://doi.org/10.1186/s40661-015-0013-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free